DE69131880T2 - Zusammenfassungen und ihren Verwendung in der Behandlung von neurologischen Krankheiten - Google Patents

Zusammenfassungen und ihren Verwendung in der Behandlung von neurologischen Krankheiten

Info

Publication number
DE69131880T2
DE69131880T2 DE69131880T DE69131880T DE69131880T2 DE 69131880 T2 DE69131880 T2 DE 69131880T2 DE 69131880 T DE69131880 T DE 69131880T DE 69131880 T DE69131880 T DE 69131880T DE 69131880 T2 DE69131880 T2 DE 69131880T2
Authority
DE
Germany
Prior art keywords
active agent
treatment
administration
neurological diseases
mono
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69131880T
Other languages
English (en)
Other versions
DE69131880D1 (de
Inventor
Joseph Gerard Masterson
Michael Myers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alkermes Pharma Ireland Ltd
Original Assignee
Elan Corp PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11039244&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69131880(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Elan Corp PLC filed Critical Elan Corp PLC
Publication of DE69131880D1 publication Critical patent/DE69131880D1/de
Application granted granted Critical
Publication of DE69131880T2 publication Critical patent/DE69131880T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
DE69131880T 1990-11-02 1991-11-01 Zusammenfassungen und ihren Verwendung in der Behandlung von neurologischen Krankheiten Expired - Lifetime DE69131880T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IE395290A IE82916B1 (en) 1990-11-02 1990-11-02 Formulations and their use in the treatment of neurological diseases

Publications (2)

Publication Number Publication Date
DE69131880D1 DE69131880D1 (de) 2000-02-03
DE69131880T2 true DE69131880T2 (de) 2000-07-20

Family

ID=11039244

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69131880T Expired - Lifetime DE69131880T2 (de) 1990-11-02 1991-11-01 Zusammenfassungen und ihren Verwendung in der Behandlung von neurologischen Krankheiten
DE201112100057 Pending DE122011100057I1 (de) 1990-11-02 2011-10-28 Zusammenfassungen und ihren Verwendung in der Behandlung von neurologischen Krankheiten.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE201112100057 Pending DE122011100057I1 (de) 1990-11-02 2011-10-28 Zusammenfassungen und ihren Verwendung in der Behandlung von neurologischen Krankheiten.

Country Status (16)

Country Link
US (3) US5370879A (de)
EP (1) EP0484186B1 (de)
JP (1) JPH04273820A (de)
AT (1) ATE188118T1 (de)
AU (1) AU657706B2 (de)
CA (1) CA2054822C (de)
CS (1) CS331391A3 (de)
DE (2) DE69131880T2 (de)
DK (1) DK0484186T3 (de)
ES (1) ES2141706T3 (de)
GR (1) GR3032769T3 (de)
HU (1) HUT74906A (de)
IE (1) IE82916B1 (de)
LU (1) LU91894I2 (de)
NZ (1) NZ240439A (de)
ZA (1) ZA918711B (de)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5221683A (en) * 1984-03-19 1993-06-22 The Rockefeller University Diaminopyridine compounds and methods of use
US5922351A (en) * 1991-03-27 1999-07-13 Bayer Corporation Lubricants for use in tabletting
CA2085785C (en) * 1992-12-18 2005-03-15 Robert R. Hansebout The use of 4-aminopyridine in the treatment of a neurological condition
JPH09501414A (ja) * 1993-06-23 1997-02-10 ジョン ジェイ． マシズ 分子経皮搬送方式
US5554381A (en) * 1993-08-09 1996-09-10 Cygnus, Inc. Low flux matrix system for delivering potent drugs transdermally
DE4332394A1 (de) * 1993-09-23 1995-03-30 Falk Pharma Gmbh Budesonid-Pellets mit kontrolliertem Freigabeprofil und Verfahren zu ihrer Herstellung
AT403988B (de) * 1994-05-18 1998-07-27 Lannacher Heilmittel Festes orales retardpräparat
TW304167B (de) * 1995-01-30 1997-05-01 Lilly Co Eli
US6245351B1 (en) 1996-03-07 2001-06-12 Takeda Chemical Industries, Ltd. Controlled-release composition
US6512010B1 (en) * 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
DE19835346A1 (de) * 1998-08-05 2000-02-10 Boehringer Ingelheim Pharma Zweiteilige Kapsel zur Aufnahme von pharmazeutischen Zubereitungen für Pulverinhalatoren
US7582680B1 (en) 1998-11-12 2009-09-01 Purdue Research Foundation Methods and compositions for treating mammalian spinal cord injuries
DK1146862T3 (da) * 1999-01-29 2003-07-21 Disphar Int Bv Farmaceutiske sammensætninger
US6432448B1 (en) 1999-02-08 2002-08-13 Fmc Corporation Edible coating composition
US6723342B1 (en) 1999-02-08 2004-04-20 Fmc Corporation Edible coating composition
ATE357914T1 (de) * 1999-02-09 2007-04-15 Uab Research Foundation Verwendung von 4-aminopyridin zur behandlung von peripheren neuropathien
US6528086B2 (en) * 1999-09-28 2003-03-04 Zars, Inc. Methods and apparatus for drug delivery involving phase changing formulations
US6500462B1 (en) 1999-10-29 2002-12-31 Fmc Corporation Edible MCC/PGA coating composition
CZ295031B6 (cs) * 1999-11-29 2005-05-18 Lts Lohmann Therapie-Systeme Ag Transdermální terapeutické systémy se zlepšenou stabilitou a způsob jejich výroby
US6419954B1 (en) * 2000-05-19 2002-07-16 Yamanouchi Pharmaceutical Co., Ltd. Tablets and methods for modified release of hydrophilic and other active agents
US6635274B1 (en) 2000-10-27 2003-10-21 Biochemics, Inc. Solution-based transdermal drug delivery system
IL155959A0 (en) 2000-11-28 2003-12-23 Fmc Corp Edible pga (propylene glycol alginate) coating composition
FR2820423B1 (fr) * 2001-02-05 2005-12-02 Assist Publ Hopitaux De Paris Tartrate et phosphate de 3,4-diaminopyridine, compositions pharmaceutiques et utilisations
ATE546146T1 (de) * 2001-04-24 2012-03-15 Purdue Research Foundation Verfahren und zusammensetzungen zur behandlung von nervengewebeverletzungen in säugetieren
US20030017133A1 (en) * 2001-06-15 2003-01-23 Wyeth (Formerly American Home Products Corporation) Mucoadhesive composition
US7125563B2 (en) * 2002-04-12 2006-10-24 Dava Pharmaceuticals, Inc. Sustained release pharmaceutical preparations and methods for producing the same
US20040028744A1 (en) * 2002-06-17 2004-02-12 Sauwaluxana Tongaree Mucoadhesive composition
US8679533B2 (en) * 2002-07-25 2014-03-25 Pharmacia Corporation Pramipexole once-daily dosage form
EP1556018A1 (de) * 2002-09-30 2005-07-27 Acusphere, Inc. Poröse mikropartikeln zur inhalation mit verlängerter freigabe
EP1576138B1 (de) 2002-11-15 2017-02-01 Idenix Pharmaceuticals LLC. 2'-methyl nukleoside in kombination mit interferon und flaviviridae-mutation
CN1745064A (zh) * 2002-12-06 2006-03-08 泊达研究基金会 用于治疗受损的哺乳动物神经组织的吡啶
US8729107B2 (en) * 2002-12-06 2014-05-20 Purdue Research Foundation Pyridines for treating injured mammalian nerve tissue
WO2004082684A1 (en) * 2003-03-17 2004-09-30 Acorda Therapeutics Stable oral formulations of aminopyridines and uses thereof
US7384970B2 (en) * 2003-03-24 2008-06-10 Irm Llc Inhibitors of cathepsin S
US20050042289A1 (en) * 2003-04-29 2005-02-24 Yamanouchi Pharma Technologies, Inc. Tablets and methods for modified release of hydrophylic and other active agents
JP2007533634A (ja) * 2003-09-30 2007-11-22 アキュスフィア， インコーポレイテッド 注射、経口、または局所用の徐放性医薬製剤
US8007826B2 (en) * 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
US8741333B2 (en) 2004-06-07 2014-06-03 Nuvo Research Inc. Compositions and methods for treating dermatitis or psoriasis
US20070196452A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Flux-enabling compositions and methods for dermal delivery of drugs
US20070190124A1 (en) * 2004-06-07 2007-08-16 Jie Zhang Two or more solidifying agent-containing compositions and methods for dermal delivery of drugs
US20070189978A1 (en) * 2004-06-07 2007-08-16 Jie Zhang Compositions and methods for dermally treating musculoskeletal pain
US20070196323A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Polyvinyl alcohol-containing compositions and methods for dermal delivery of drugs
US20070196293A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Compositions and methods for treating photo damaged skin
US8907153B2 (en) 2004-06-07 2014-12-09 Nuvo Research Inc. Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same
US20070196453A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Two or more non-volatile solvent-containing compositions and methods for dermal delivery of drugs
US20070196457A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Two or more volatile solvent-containing compositions and methods for dermal delivery of drugs
US8741332B2 (en) * 2004-06-07 2014-06-03 Nuvo Research Inc. Compositions and methods for dermally treating neuropathic pain
US20080019927A1 (en) * 2004-06-07 2008-01-24 Jie Zhang Compositions and methods for dermally treating neuropathy with minoxidil
US20070196325A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Compositions and methods for dermally treating infections
US20080280973A1 (en) * 2004-06-28 2008-11-13 Wender Paul A Laulimalide Analogues as Therapeutic Agents
KR20070050081A (ko) * 2004-08-13 2007-05-14 베링거 인겔하임 인터내셔날 게엠베하 프라미펙솔 또는 약제학적으로 허용되는 이의 염을포함하는 연장 방출형 펠렛 제형, 이의 제조방법 및 이의용도
KR101052436B1 (ko) * 2004-08-13 2011-07-29 베링거 인겔하임 인터내셔날 게엠베하 프라미펙솔 또는 약제학적으로 허용되는 이의 염을함유하는 연장 방출형 정제 제형, 이의 제조방법 및 이의용도
US7884079B2 (en) * 2004-12-27 2011-02-08 Miller Landon C G 4-aminopyridine and a pharmaceutical composition for treatment of neuronal disorders
US7932275B2 (en) * 2004-10-29 2011-04-26 Merck, Sharp & Dohme Corp. 2-aminopyridine compounds useful as β-secretase inhibitors for the treatment of alzheimer's disease
US7838522B2 (en) * 2004-11-17 2010-11-23 Ares Trading S.A. Benzothiazole formulations and use thereof
JP5021488B2 (ja) * 2004-12-21 2012-09-05 メルク セローノ ソシエテ アノニム スルホニルアミノ環式誘導体及びその使用
US8691835B2 (en) * 2004-12-27 2014-04-08 Landon C. G. Miller 4 aminopyridine and a pharmaceutical composition for treatment of neuronal disorders
DE102005001332A1 (de) * 2005-01-11 2006-07-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Zweiteilige Kapsel mit Vorverschluss zur Aufnahme von pharmazeutischen Zubereitungen für Pulverinhalatoren
DK1844032T3 (da) * 2005-01-31 2011-10-24 Merck Serono Sa N-hydroxyamid-derivater og deres anvendelse
KR20080044836A (ko) 2005-07-15 2008-05-21 라보라뚜와르 세로노 에스. 에이. 자궁내막증 치료용 ｊｎｋ 억제제
BRPI0613042A2 (pt) * 2005-07-15 2010-12-14 Serono Lab inibidores de jnk para o tratamento de endometriose
KR20080036084A (ko) * 2005-07-15 2008-04-24 라보라뚜와르 세로노 에스. 에이. 자가면역 및／또는 염증성 질환 치료용 Ｇｌｅｐｐ―１억제제
US8778395B2 (en) * 2005-08-11 2014-07-15 Andrx Labs, Llc Diltiazem controlled release formulation and method of manufacture
CA2616479A1 (en) * 2005-09-01 2007-03-08 Ares Trading S.A. Treatment of optic neuritis
FR2894143B1 (fr) * 2005-12-01 2008-05-02 Pierre Fabre Medicament Sa Composition a liberation prolongee de l'actif, son procede de preparation et son utilisation.
EP1973523A2 (de) * 2005-12-15 2008-10-01 Acusphere, Inc. Verfahren zur herstellung von pharmazeutischen formulierungen auf teilchenbasis zur pulmonalen oder nasalen verabreichung
WO2007070843A2 (en) * 2005-12-15 2007-06-21 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for oral administration
WO2007090883A1 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Extended release formulation
WO2007090881A2 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Modified release formulation
US20070280972A1 (en) * 2006-04-25 2007-12-06 Zars, Inc. Adhesive solid gel-forming formulations for dermal drug delivery
DE102006027791A1 (de) * 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag AchE-NMDA-Kombinationswafer
US20080155889A1 (en) * 2006-12-04 2008-07-03 Chevron U.S.A. Inc. Fischer-tropsch derived diesel fuel and process for making same
US20150111930A1 (en) * 2013-10-23 2015-04-23 Afgin Pharma, Llc Topical regional neuro-affective therapy
US20100034968A1 (en) * 2008-08-07 2010-02-11 Vector Corporation Polymer coating process using dry glidant in a rotor processor
US20100034967A1 (en) * 2008-08-07 2010-02-11 Vector Corporation Dry polymer layering using a rotor processor
US8807070B2 (en) * 2008-08-07 2014-08-19 Vector Corporation Rotor processor for dry powders
US9012477B2 (en) * 2009-01-06 2015-04-21 Nuvo Research Inc. Method of treating neuropathic pain
US20120029035A1 (en) * 2009-02-11 2012-02-02 Acorda Therapeutics, Inc. Compositions and methods for extended therapy with aminopyridines
JO3348B1 (ar) * 2009-08-11 2019-03-13 Acorda Therapeutics Inc استخدام 4- بايريدين امينو لتحسين الادراك العصبي و/او التلف النفسي لدى مرضى يعانون من نقص النُخاعين وغير ذلك من امراض الجهاز العصبي
BR112012017554B8 (pt) 2010-01-14 2021-05-25 Crescita Therapeutics Inc formulações de anestésicas locais formadoras de sólido para controle da dor
CA2840591A1 (en) 2011-06-30 2013-01-03 Biomarin Pharmaceuticals, Inc. Methods of administering 3,4-diaminopyridine
TWI592156B (zh) 2011-10-04 2017-07-21 艾可達醫療公司 使用胺基吡啶以治療與中風有關之感覺動作損傷之方法
EP2785184B1 (de) 2011-11-30 2020-06-10 Emory University ZUSAMMENSETZUNGEN ENTHAlTEND JAK-HEMMER UND HAART-MEDIKAMENTE ZUR VORBEUGUNG ODER BEHANDLUNG VON HIV
EP3381455A1 (de) 2012-02-13 2018-10-03 Acorda Therapeutics, Inc. Verfahren zur behandlung einer störung des gangs und/oder des gleichgewichts bei patienten mit multipler sklerose mit einem aminopyrimidin
WO2014028387A1 (en) 2012-08-13 2014-02-20 Acorda Therapeutics, Inc. Methods for improving walking capacity in patients with multiple sclerosis using an aminopyridine
WO2014093475A1 (en) 2012-12-11 2014-06-19 Acorda Therapeutics, Inc. Methods for treating parkinson's disease using aminopyridines
EP3243516A1 (de) 2013-04-15 2017-11-15 Acorda Therapeutics, Inc. Verfahren zur behandlung von sensomotorischen störungen im zusammenhang mit bestimmten typen von schlaganfall mithilfe von aminopyridinen
JP6100150B2 (ja) * 2013-12-06 2017-03-22 久光製薬株式会社 ４−アミノピリジン含有貼付剤
CN106511293B (zh) 2015-09-11 2020-08-04 法德生技药品股份有限公司 含有达方吡啶的缓释口服制剂及其用途
RU2607655C1 (ru) * 2015-09-25 2017-01-10 Общество С Ограниченной Ответственностью "Валента-Интеллект" Способ получения таблеток далфампридина пролонгированного действия
EP3355865A1 (de) 2015-09-29 2018-08-08 Acorda Therapeutics, Inc. Zusammensetzungen aus 4-aminopyridin mit verzögerter freisetzung
WO2018186866A1 (en) 2017-04-06 2018-10-11 Cobb Joseph E Jr Sustained release compositions of 4-aminopyridine
DE102017115701B4 (de) * 2017-07-12 2022-03-03 Lts Lohmann Therapie-Systeme Ag Fampridin-TTS
EP3687539A4 (de) * 2017-09-25 2021-07-07 Aizant Drug Research Solutions Private Limited Stabile pharmazeutische zusammensetzungen von dalfampridin
US10213393B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Feleõsségû Társaság Composition and method for treating neurological disease
US10213394B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease
US20190247331A1 (en) 2018-02-15 2019-08-15 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease
CN114712321A (zh) * 2022-04-22 2022-07-08 河北一品生物医药有限公司 磷酸二氨基吡啶缓释片及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4386095A (en) * 1982-02-22 1983-05-31 Cornell Research Foundation, Inc. Diaminopyridines to improve cognition
IE53703B1 (en) * 1982-12-13 1989-01-18 Elan Corp Plc Drug delivery device
IE54286B1 (en) * 1983-01-18 1989-08-16 Elan Corp Plc Drug delivery device
IE56459B1 (en) * 1983-12-21 1991-08-14 Elan Corp Ltd Controlled absorption pharmaceutical formulation
US4894240A (en) * 1983-12-22 1990-01-16 Elan Corporation Plc Controlled absorption diltiazem formulation for once-daily administration
IE56999B1 (en) * 1983-12-22 1992-03-11 Elan Corp Plc Pharmaceutical formulation
US4562196A (en) * 1984-04-06 1985-12-31 Nelson Research & Development 2,4-Diaminopyridine as a pharmacologic agent
IL86170A (en) * 1987-05-01 1992-12-01 Elan Transdermal Ltd Preparations and compositions comprising nicotine for percutaneous administration
IE64726B1 (en) * 1987-11-20 1995-08-23 Elan Corp Plc Pharmaceutical formulations for preventing drug tolerance

Also Published As

Publication number Publication date
CA2054822C (en) 2004-04-20
AU657706B2 (en) 1995-03-23
ATE188118T1 (de) 2000-01-15
ES2141706T3 (es) 2000-04-01
LU91894I2 (fr) 2011-12-28
AU8696191A (en) 1992-05-07
NZ240439A (en) 1995-03-28
DK0484186T3 (da) 2000-04-17
GR3032769T3 (en) 2000-06-30
EP0484186B1 (de) 1999-12-29
DE69131880D1 (de) 2000-02-03
HUT74906A (en) 1997-03-28
CS331391A3 (en) 1992-05-13
JPH04273820A (ja) 1992-09-30
ZA918711B (en) 1992-08-26
DE122011100057I1 (de) 2012-03-15
US5540938A (en) 1996-07-30
US5370879A (en) 1994-12-06
IE82916B1 (en) 2003-06-11
US5580580A (en) 1996-12-03
EP0484186A1 (de) 1992-05-06
CA2054822A1 (en) 1992-05-03
IE903952A1 (en) 1992-05-22
HU913447D0 (en) 1992-01-28

Similar Documents

Publication Publication Date Title
DE69131880T2 (de) Zusammenfassungen und ihren Verwendung in der Behandlung von neurologischen Krankheiten
DE3779500T2 (de) Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
ATE328590T1 (de) Pharmazeutische zusammensetzungen enthaltend s-(- )-n-propargyl-1-aminoindan
DE69815122T2 (de) Saccharid-enthaltende zubereitungen zur behandlung von alzheimerschen erkrankung und von weiteren amyloidosen
DE3382641T2 (de) Arzneimittel fuer die therapeutische behandlung von alopezie.
DK0713701T3 (da) 2-Brommelatonin til behandling af søvnforstyrrelser
HUT71889A (en) Pharmaceutical compositions containing terfenadine metabolites and their optically pure isomers for treating allergic disorders
DE69329400D1 (de) L-Dopa Ester enthaltende Zusammensetzung
ATE99932T1 (de) Verwendung von pyrrolicloncarbonsaeurealkylestern zur herstellung eines arzneimittels zur behandlung von ichtyosis.
DK0412554T3 (da) Sustained-release-præparat til administration i hjernen
CA2143610A1 (en) Use of norastemizole for the treatment of allergic disorders
DE69129563T2 (de) Epidermis-Wachstumsfaktor als Arzneimittel zur Wiederherstellung der Neuronen der Substantia nigra in der Behandlung nervenzerstörender Störungen
ATE89737T1 (de) Behandlung von leukozytstoerungen mit gm-csf.
DE69007065T2 (de) Verwendung von Diadenosin-5',5'''-p1,p4-tetraphosphat zur Herstellung eines Arzneimittels zur Behandlung von Herzkrankheiten.
DK1707568T3 (da) Farmaceutisk sammensætning til anvendelse i behandlingen af ovariecancer hos et menneske, der har sygdommen
IT8919216A0 (it) Dispositivo per la cura chirurgica dell'astigmatismo.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R081 Change of applicant/patentee

Owner name: ALKERMES PHARMA IRELAND LIMITED; IE

Free format text: PRODUCT NAME: FAMPYRA - ZUSAMMENSETZUNG UMFASSEND FAMPRIDIN; REGISTRATION NO/DATE: EU/1/11/699/001-002 20110720; FORMER OWNER: ALKERMES PHARMA IRELAND LIMITED, ATHLONE, IE

Spc suppl protection certif: 122011100057

Filing date: 20111028

Expiry date: 20111102

Owner name: ALKERMES PHARMA IRELAND LIMITED, IE

Free format text: FORMER OWNER: ALKERMES PHARMA IRELAND LIMITED, ATHLONE, IE

Spc suppl protection certif: 122011100057

Filing date: 20111028

Expiry date: 20111102

R082 Change of representative

Free format text: PRODUCT NAME: FAMPYRA - ZUSAMMENSETZUNG UMFASSEND FAMPRIDIN; REGISTRATION NO/DATE: EU/1/11/699/001-002 20110720

Spc suppl protection certif: 122011100057

Filing date: 20111028

Expiry date: 20111102

Representative=s name: WEICKMANN & WEICKMANN

Free format text: PRODUCT NAME: FAMPYRA - ZUSAMMENSETZUNG UMFASSEND FAMPRIDIN; REGISTRATION NO/DATE: EU/1/11/699/001-002 20110720

Spc suppl protection certif: 122011100057

Filing date: 20111028

Expiry date: 20111102

Representative=s name: UEXKUELL & STOLBERG, DE

R082 Change of representative

Free format text: PRODUCT NAME: FAMPYRA - ZUSAMMENSETZUNG UMFASSEND FAMPRIDIN; REGISTRATION NO/DATE: EU/1/11/699/001-002 20110720

Spc suppl protection certif: 122011100057

Filing date: 20111028

Expiry date: 20111102

Representative=s name: UEXKUELL & STOLBERG, DE